Approval · Notice of Compliance 37245 · 2026
RYSTIGGO: Notice of Compliance 37245
Issued March 31, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37245
- Date
- March 31, 2026
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New presentation
Products in this notice
Medicinal ingredients
- ROZANOLIXIZUMAB 280 MG per 2ML
- ROZANOLIXIZUMAB 420 MG per 3ML
- ROZANOLIXIZUMAB 560 MG per 4ML
- ROZANOLIXIZUMAB 840 MG per 6ML